Khan Sana Farooq
Division of Nephrology, University of Virginia Health System, Charlottesville, VA 22908, USA.
J Clin Med. 2022 Jun 8;11(12):3270. doi: 10.3390/jcm11123270.
Since the advent and predominant use of extracorporeal therapies for renal replacement therapies for acute kidney injury, the use of peritoneal dialysis has largely been limited to specific resource-limited settings. This review highlights the current data available for the utilization of peritoneal dialysis for acute kidney injury. Though the current randomized controlled trials have small patient numbers, they have demonstrated peritoneal dialysis to be an appropriate modality for dialysis therapy in acute kidney injury. Current outcomes do not show a difference in mortality, renal recovery rates, or infectious complications when compared to extracorporeal treatments. However, there is a marked heterogeneity in these trials, and more standardized reporting of trial design, techniques, complications, and outcomes is needed.
自从体外治疗用于急性肾损伤的肾脏替代治疗出现并得到广泛应用以来，腹膜透析的使用在很大程度上已局限于特定资源有限的环境。本综述重点介绍了目前可用于急性肾损伤腹膜透析的现有数据。尽管目前的随机对照试验患者数量较少，但已证明腹膜透析是急性肾损伤透析治疗的一种合适方式。与体外治疗相比，目前的结果在死亡率、肾脏恢复率或感染并发症方面并无差异。然而，这些试验存在明显的异质性，需要对试验设计、技术、并发症和结果进行更标准化的报告。
